Debbie Rigby takes a look at the latest in research news
An inhaler company whose products are used extensively by people with COPD and asthma, has just been taken over by a large international tobacco company. The authors conclude that consideration based on beneficence, non-maleficence, autonomy, and distributive justice demonstrates strong ethical reasons to support switching inhalers, which can be achieved without any significant risk to patient outcomes.
Authorea. August 24, 2021.
Over-reliance on short-acting β2-agonists (SABAs) is common in clinical practice. In this retrospective analysis, excessive SABA use was defined as ≥400 inhalations per year. Among 1161 patients, 25% overused SABAs. For patients using asthma medication the odds of having an exacerbation were 2.9 times higher if they used an inappropriate number of SABAs than if SABAs were used appropriately.
Family Practice 2021;38(5):612-6.
Semi-structured interviews with 23 Indian migrants living in Sydney highlights the need for tailored interventions, including education, that focus on factors that impact medication adherence from initiation to discontinuation of therapy. A few participants discontinued taking their medicine and tried Ayurvedic medicine.
Frontiers in Pharmacology, 20 September 2021.
In this large US population-based cohort study use of SGLT2 inhibitors versus GLP-1 RAs was associated with consistent reductions in the risk of hospitalization for heart failure among patients with type 2 diabetes with and without cardiovascular disease (CVD), although the absolute benefit was greater in patients with CVD. There were no large differences in risk for myocardial infarction or stroke among patients with and without CVD.
Annals of Internal Medicine 2021.